

Composition	$H_2N - NH_2 \cdot H_2O$
Chemical Formula	$N_2H_4 - H_2O$
CAS Nr Monohydrate	7803-57-8
Reach Registration Nr	01-2119492624-31-0004
EINECS Nr	206-114-9

Hydrazine hydrate solution containing a purely organic activator

COMMERCIAL SPECIFICATIONS

SPECIFICATION	UNIT	VALUE	ANALYSIS METHOD
Assay	% weight	24 +/- 0,5	LABO/3/07 (Acidimetry)
Hydrazine content	% weight	15,4 +/- 0,4	LABO/3/07 (Acidimetry)
Chlorine content	ppm	1 max	LABO/3/187 (Ionic chromatography)
Sulphate content	ppm	1 max	LABO/3/187 (Ionic chromatography)
Inorganic residue	ppm	20 max	LABO/3/05 (calcination)
Sodium content	ppm	1 max	LABO/3/03 (spectrometry)
Iron content	ppm	1 max	LABO/3/03 (spectrometry)

MAIN PROPERTIES

PHYSICAL PROPERTIES	UNIT	VALUE
Boiling point (1 ATM)	° C	102 to 104
Freezing point	° C	-24 to -12
Vapor pressure at 20 ° C	hPa	15 to 20
Density at 20°	Kg/l	1,010 to 1,020
pH-1% in water solution		10.6
Water solubility		Totally miscible at 20 ° C
Appearance		Clear, colorless to slightly colored liquid (red-brown)

PACKAGING

- Bulk by Isotank for 20 Ton/ 24 Ton/ 28 Ton
- PE Drums for 200 kg and 25 kg
- PE IBC 1000 kg
- Steel returnable IBC for 1000 kg

All plastic packaging can be equipped with STS (safety transfer system) for safe handling of the product.

MAIN APPLICATIONS

Corrosion inhibitor for:

- Waste or boiler water and effluent treatment, in high pressure industrial boiler plants.
- Removing dissolved oxygen at lower/ambient temperatures

SAFETY AND STORAGE

- Please refer to the corresponding ARKEMA Safety Data Sheet **N° 001799-001** before any use.
- Avoid any contact with hot surfaces (e.g. areas exposed to the sun)
- Product Storage Time: Maximum 12 months from the delivery date, if stored as prescribed in the Safety Data Sheet.

TRANSPORT INFORMATION

Regulation	UN nr.	Shipping Name	Class	Label	PG	Environmental hazardous
ADR	3293	Hydrazine, Aqueous solution	6.1	6.1	III	Yes
ADNR	3293	Hydrazine, Aqueous solution	6.1	6.1	III	Yes
RID	3293	Hydrazine, Aqueous solution	6.1	6.1	III	Yes
IATA Cargo	3293	Hydrazine, Aqueous solution	6.1	6.1	III	Yes
IATA Passenger	3293	Hydrazine, Aqueous solution	6.1	6.1	III	Yes
IMDG	3293	Hydrazine, Aqueous solution	6.1	6.1	III	Marine pollutant

PRODUCTION SITE.

The production site is located in Lannemezan (France)

The plant is certified:

- **ISO 14001** since 1997
- **Seveso class 2 high level**
- For more informations visit us: <http://www.arkema.com/en/products/>

Updated: 29/12/2016 – Ref AQ/3/50 LNZ

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, Arkema expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations.

Arkema has implemented a Medical Policy regarding the use of Arkema products in medical devices applications that are in contact with the body or circulating bodily fluids (<http://www.arkema.com/en/social-responsibility/responsible-product-management/medical-device-policy/index.html>) Arkema has designated medical grades to be used for such medical device applications. Products that have not been designated as medical grades are not authorized by Arkema for use in medical device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in medical device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices.

It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies). It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations. Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.

Headquarters: Arkema France
420, rue d'Estienne d'Orves
92705 Colombes Cedex – France
Tel.: +33 (0)1 49 00 80 80
Fax: +33 (0)1 49 00 83 96